Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2025-03-26 DOI:10.1016/j.cllc.2025.03.006

Fabian J Bolte, Sean C Dougherty, Abigail O Danos, Alia C Lynch, Yaroslav Shvorak, Sarah Statler, Ryan D Gentzler, Richard D Hall

{"title":"Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.","authors":"Fabian J Bolte, Sean C Dougherty, Abigail O Danos, Alia C Lynch, Yaroslav Shvorak, Sarah Statler, Ryan D Gentzler, Richard D Hall","doi":"10.1016/j.cllc.2025.03.006","DOIUrl":null,"url":null,"abstract":"Background: Tarlatamab, a bispecific T-cell engager, has shown promising results in previously treated small cell lung cancer (SCLC) patients in the DeLLphi-300 and DeLLphi-301 trials. However, reports on outcomes in more diverse, real-world patient populations are limited.Methods: We retrospectively evaluated safety and efficacy outcomes of all patients who were treated with tarlatamab at the University of Virginia between May and October 2024.Results: Our analysis included 21 patients with SCLC and 1 patient with DLL-3 positive atypical carcinoid. The median age of patients was 66 years (range, 41-80 years), with 59.1% being females. Most patients (85.7%) had extensive stage SCLC at diagnosis. Brain metastases were present in 9 (40.9%) patients and liver metastasis in 14 (63.8%) patients. A total of 18 (81.8%) patients would not have met the DeLLphi-301 inclusion and exclusion criteria. Cytokine release syndrome (CRS) occurred in 16 (72.7%) patients; the median time of onset was 15.8 hours (9.1-18.8) after tarlatamab infusion. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 9 (40.9%) patients, with higher rates and grades observed in patients with untreated brain metastases. The median time of onset was 14.8 h ([IQR] 7.7-22.1) after tarlatamab infusion. After a median follow-up of 6.7 months, the overall response rate (ORR) was 42.9% in SCLC patients.Conclusions: Tarlatamab is a promising treatment option for heavily pretreated small cell lung cancer patients. We observed higher rates of CRS and ICANS during the first treatment cycle suggesting that real-world safety outcomes may differ from clinical trial data.","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2025.03.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tarlatamab, a bispecific T-cell engager, has shown promising results in previously treated small cell lung cancer (SCLC) patients in the DeLLphi-300 and DeLLphi-301 trials. However, reports on outcomes in more diverse, real-world patient populations are limited.

Methods: We retrospectively evaluated safety and efficacy outcomes of all patients who were treated with tarlatamab at the University of Virginia between May and October 2024.

Results: Our analysis included 21 patients with SCLC and 1 patient with DLL-3 positive atypical carcinoid. The median age of patients was 66 years (range, 41-80 years), with 59.1% being females. Most patients (85.7%) had extensive stage SCLC at diagnosis. Brain metastases were present in 9 (40.9%) patients and liver metastasis in 14 (63.8%) patients. A total of 18 (81.8%) patients would not have met the DeLLphi-301 inclusion and exclusion criteria. Cytokine release syndrome (CRS) occurred in 16 (72.7%) patients; the median time of onset was 15.8 hours (9.1-18.8) after tarlatamab infusion. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 9 (40.9%) patients, with higher rates and grades observed in patients with untreated brain metastases. The median time of onset was 14.8 h ([IQR] 7.7-22.1) after tarlatamab infusion. After a median follow-up of 6.7 months, the overall response rate (ORR) was 42.9% in SCLC patients.

Conclusions: Tarlatamab is a promising treatment option for heavily pretreated small cell lung cancer patients. We observed higher rates of CRS and ICANS during the first treatment cycle suggesting that real-world safety outcomes may differ from clinical trial data.

查看原文本刊更多论文

塔拉他单抗治疗小细胞肺癌的实际疗效，包括未经治疗的脑转移患者。

背景：Tarlatamab是一种双特异性t细胞参与剂，在delphi -300和delphi -301试验中，在先前治疗的小细胞肺癌（SCLC）患者中显示出令人鼓舞的效果。然而，关于更多样化的现实世界患者群体的结果报告是有限的。方法：我们回顾性评估2024年5月至10月在弗吉尼亚大学接受塔拉他单抗治疗的所有患者的安全性和有效性结果。结果：我们分析了21例SCLC患者和1例dl3阳性的非典型类癌患者。患者年龄中位数为66岁（41 ~ 80岁），女性占59.1%。大多数患者（85.7%）在诊断时为广泛分期SCLC。脑转移9例（40.9%），肝转移14例（63.8%）。共有18例（81.8%）患者不符合delphi -301纳入和排除标准。发生细胞因子释放综合征（CRS） 16例（72.7%）；滴注塔拉他单抗后中位发病时间为15.8小时（9.1 ~ 18.8小时）。免疫效应细胞相关神经毒性综合征（ICANS）发生在9例（40.9%）患者中，在未经治疗的脑转移患者中观察到更高的发生率和级别。滴注塔拉他单抗后中位发病时间为14.8 h （[IQR] 7.7 ~ 22.1）。中位随访6.7个月后，SCLC患者的总缓解率（ORR）为42.9%。结论：塔拉他抗对于重度预处理的小细胞肺癌患者是一种很有前景的治疗选择。我们观察到在第一个治疗周期CRS和ICANS发生率较高，这表明现实世界的安全性结果可能与临床试验数据不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.